Brenda M. Sandmaier, MDDr. Sandmaier is a medical oncologist who treats patients with hematologic malignancies including leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome. Her focus of research is in the area of reduced intensity transplantation and the use of alternative donors.
Patient Care Philosophy:
My goal is to provide information integrated with knowledge from both research and clinical experience to patients and their families to allow the patient to actively participate in treatment decisions. This will build a partnership between the patient and the clinical team for the duration of their treatment.
- Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
- Professor, Medical Oncology Division, University of Washington School of Medicine
Hematopoietic cell transplantation using HLA-matched & mismatched donors; Development of nonmyeloablative conditioning regimens.
Education And Training
- University of Alberta, Edmonton, Alberta, Canada. BSc Genetics
- University of Alberta Medical School, Edmonton, Alberta, Canada. Medical Degree
- Residency in Internal Medicine, Kaiser Permanente Medical Center, Santa Clara, California
- Fellowship, Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington
For more information about Dr. Brenda M. Sandmaier's clinical and research expertise, click here.
- Natural Killer Cell Therapy Post Non-Myeloablative BMT (FHCRC-2230)
- Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant (FHCRC-1825)
- Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing GVHD for Undergoing Donor Peripheral Blood Stem Cell Transplant (FHCRC-2206)
- Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (FHCRC-2448)
- AC220 Post Transplant for Acute Myeloid Leukemia (2487)